Global Plasma Fractionation Market - WishTree Insight

Global Plasma Fractionation Treatment Market -Market Size, Share & Industry Trends, Growth Analysis Report by Product Type, By Consumption, and Forecast 2021 – 2031

Global plasma fractionation treatment Market by Application (Hemato-Oncology, Immunology, Hematology, Rheumatology, Neurology), Product (Albumins, Protease Inhibitors, Anticoagulants, Coagulation Factors, Immunoglobulin), and Regions (The Asia Pacific, Middle East Africa, Europe, North America, and Latin America) - Global Industry Analysis, Share, Growth, Trends, Size, and Forecast 2021 – 2031

The global plasma fractionation treatment market size was valued at USD 24.6 billion in 2021 and is expected to surpass USD 42.6 billion by 2031, expanding at a CAGR of 6.7 % during the forecast period, 2021–2031. The growth of the market is attributed to the increasing use of immunoglobulins for different therapeutic areas, plasma collection, the growing prevalence of respiratory diseases, alpha-1-antitrypsin deficiency (AATD), and the rising geriatric population.

INTRODUCTION

Plasma is a crucial component of blood. Human plasma has a concentration of different proteins, which is beneficial for producing therapeutic plasma products. It is a composition of salts, ions, minerals, nutrients, and proteins in a solution. Plasma fractionation states to the processing of plasma for different therapies and medicinal products. The fractionation process breaks the plasma into individual proteins using mechanical separation methods such as filtration, chromatography, precipitation, and centrifugation. To extract specific therapeutic proteins the fractionation processes, use pH, alcohol concentrations, temperature, and time. The increasing technology complexity and treatment reduction have resulted in the development of protein therapeutics, improvements in purity, and quality.

The fractionation process of plasma such as immunoglobulin, anticoagulants, coagulating factors, protease inhibitors, albumins, and others are used to treat, prevent and manage threatening human illnesses and injuries. The proteins extracted from the plasma fractionation process are categorized into three main classes naming immunoglobulin, clotting factors, and albumins.

Immunoglobulin is used to treat autoimmune diseases and improves the immune system and its response. The clotting factors are beneficial for the treatment of blood disorders such as hemophilia. Albumins are applicable to treat exhausted albumin levels or fluid loss from the body.

The plasma fractionation process is based on the solubility of products and their chemical and physical positions such as ionic strengths, temperature, pH levels, and others.

Market Trends, Drivers, Restraints, and Opportunities

• The increased awareness amongst people regarding various liver and chronic related diseases are the major factor fueling the growth of this market.
• The rising use of immunoglobulins and alpha-1-antitrypsin in medicines is also estimated to increase this market.
• The increasing health care facilities, plasma collection centers, and favorable government policies are also identified as drivers of the plasma fractionation market.
• High costs and limited reimbursements available are some of the restraining factors in this market.

Scope of the Report

Market Segment Insights

The neurology segment is expected to expand at a rapid pace

Based on application, the global plasma fractionation treatment market is divided into hemato-oncology, immunology, hematology, rheumatology, and neurology. The neurology segment is expected to expand at a rapid pace during the forecast period. This segment has grown due to IVIg's rapid response time compared to steroids or oral immunosuppressants and its effectiveness in treating many neurological disorders.

The immunoglobulin segment is projected to register a considerable CAGR

based on product, the market is segregated into albumins, protease inhibitors, anticoagulants, coagulation factors, and immunoglobulin. The immunoglobulin segment is projected to register a considerable CAGR during the forecast period. The growing adoption of SClg and the increasing on-label and off-label use of immunoglobulins for various indications are expected to be key factors in the growth of the segment. On the other hand, the albumins and coagulation factor segments are anticipated to account for a major market share during the forecast period.

The North American region is anticipated to constitute a key market share

In terms of regions, the GLOBAL PLASMA FRACTIONATION TREATMENT market is classified as the Asia Pacific, Middle East Africa, Europe, North America, and Latin America. The market of the North American region is expected to constitute a key share of the market during the projected period due to the use of immunoglobulin in various therapeutic areas, high medical facilities, and a rising number of chronic diseases. However, the market of the Asia Pacific and Europe region is anticipated to expand at a rapid pace during the forecast period with key players adopting an expansion strategy in this region to gain maximum market share in the coming years. Countries in the region like China and India are offering ample opportunities for the growth of the plasma fractionation market with their high population base. Key factors such as changing positive attitudes and behavior towards healthcare and favorable government regulations also drive the plasma fractionation market in the Asia Pacific region.

Competitive Landscape

Key players competing in the global plasma fractionation treatment market are Shire (Ireland); CSL (Australia); Octapharma (Switzerland); Grifols (Spain); Kedrion (Italy); LFB (France); China Biologic Products (China); Biotest (Germany); Bio Products Laboratory (UK); Sanquin (Netherlands).

FAQs

How much is the market worth?

The global plasma fractionation treatment market size was valued at USD 24.6 billion in 2021 and is expected to surpass USD 42.6 billion by 2031.

Mention the market size of the Global plasma fractionation treatment in 2021.

The market size of the Global plasma fractionation treatment in 2021 was 24.6 billion.

During the forecast period, what is the CAGR of the market?

During the forecast period, the CAGR of the market is expected to be 6.7%.

What are the key drivers of the market?

The growth of the market is attributed to the increasing use of immunoglobulins for different therapeutic areas, plasma collection, the growing prevalence of respiratory diseases, alpha-1-antitrypsin deficiency (AATD), and the rising geriatric population.

What segments are covered in the Global plasma fractionation treatment report?

The segments covered in the Global plasma fractionation treatment report are Application (Hemato-Oncology, Immunology, Hematology, Rheumatology, Neurology), Product (Albumins, Protease Inhibitors, Anticoagulants, Coagulation Factors, Immunoglobulin)

Mention the region is expected to hold the highest share in the Global plasma fractionation treatment.

The North American region is expected to hold the highest share in the Global plasma fractionation treatment.

Mention the key players in the market.

The key players in the market are Shire (Ireland); CSL (Australia); Octapharma (Switzerland); Grifols (Spain); Kedrion (Italy); LFB (France); China Biologic Products (China); Biotest (Germany); Bio Products Laboratory (UK); Sanquin (Netherlands).